- Home - Sana Biotechnology
Repairing and controlling genes in cells or replacing missing or damaged cells can solve the underlying cause of many diseases These emerging capabilities will create novel medicines that meaningfully improve patient outcomes, and Sana aims to lead the way
- Join Us - Sana Biotechnology
We thoughtfully design our programs, coverage, and guidelines with the needs of our employees in mind Our goal is to make available a diverse offering of health and well-being resources and support so that employees can thrive and do the best work of their lives Learn more about Sana’s Benefits
- Our Pipeline - Sana Biotechnology
Sana is committed to developing safe and effective engineered cells as medicines, which involves evaluation in clinical trials followed by submission of the trial results to regulatory agencies, such as the U S Food and Drug Administration (FDA)
- Steve Harr, MD - Sana Biotechnology
Steve Harr, MD, is President and Chief Executive Officer of Sana Biotechnology Prior to co-founding Sana, Steve served as Chief Financial Officer and Head of Corporate Development for Juno Therapeutics until its acquisition by Celgene in early 2018
- Sana Biotechnology, Inc News Releases
SEATTLE, Aug 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September
- If you have the right to work, dont let anyone take it away - Sana
If you have the skills, experience, and legal right to work, your citizenship or immigration status shouldn’t get in the way Neither should the place you were born or another aspect of your national origin A part of U S immigration laws protects legally-authorized workers from discri-mination based on their citizenship status and national origin You can read this law at
- sana. com
Sana’s in vivo Cell Engineering platform aims to provide solutions for patients that current gene therapies cannot address Success will require creative science, experienced product and clinical development strategies, and aggregating important technologies
- News Releases - Sana Biotechnology, Inc
SEATTLE, Aug 26, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September
|